ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DRRX Durect Corp

1.23
0.03 (2.50%)
Last Updated: 15:04:30
Delayed by 15 minutes
Share Name Share Symbol Market Type
Durect Corp NASDAQ:DRRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 2.50% 1.23 1.20 1.23 1.23 1.20 1.22 17,954 15:04:30

DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call

24/10/2014 9:30pm

PR Newswire (US)


Durect (NASDAQ:DRRX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Durect Charts.

CUPERTINO, Calif., Oct. 24, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time.

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR, SABER®, ORADUR®, and TRANSDUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

Logo - http://photos.prnewswire.com/prnh/20020717/DRRXLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-third-quarter-2014-earnings-conference-call-676096238.html

SOURCE DURECT Corporation

Copyright 2014 PR Newswire

1 Year Durect Chart

1 Year Durect Chart

1 Month Durect Chart

1 Month Durect Chart

Your Recent History

Delayed Upgrade Clock